TY - JOUR
T1 - Discontinuation and remission rates and social functioning in patients with schizophrenia receiving second-generation antipsychotics
T2 - 52-week evaluation of JUMPs, a randomized, open-label study
AU - Ishigooka, Jun
AU - Nakagome, Kazuyuki
AU - Ohmori, Tetsuro
AU - Iwata, Nakao
AU - Inada, Ken
AU - Iga, Jun ichi
AU - Kishi, Taro
AU - Fujita, Kiyoshi
AU - Kikuchi, Yuka
AU - Shichijo, Toshiaki
AU - Tabuse, Hideaki
AU - Koretsune, Shotatsu
AU - Terada, Hiroshi
AU - Terada, Haruko
AU - Kishimoto, Toshifumi
AU - Tsutsumi, Yuichiro
AU - Kanda, Yoshiki
AU - Ohi, Kazutaka
AU - Sekiyama, Kanji
N1 - Funding Information:
T. Kishi has received speaker's honoraria from Daiichi Sankyo, Dainippon Sumitomo, Eisai, Janssen, Otsuka, Meiji, MSD, Yoshitomi, and Tanabe‐Mitsubishi and has received a Health Labour Sciences Research Grant, Grant‐in‐Aid for Scientific Research (C), and Fujita Health University School of Medicine research grant.
Funding Information:
K. Inada reports personal fees from Dainippon Sumitomo, Eisai, Eli Lilly, Janssen, Meiji Seika Pharma, Mochida, MSD, Novartis, Otsuka, Shionogi, Tanabe‐Mitsubishi, and Yoshitomi and a grant from MSD, outside the submitted work.
Funding Information:
Editorial support, in the form of medical writing, assembling tables and creating high‐resolution images based on the authors' detailed directions, collating author comments, copyediting, fact checking, and referencing, was provided by Annirudha Chillar, MD, PhD, of Cactus Life Sciences (part of Cactus Communications) and funded by The Waksman Foundation of Japan Inc. This work was supported by a research grant from The Waksman Foundation of Japan Inc. The funding source had no role in study planning, implementation, and reporting of study results or interpretation; the study implementation does not conflict with patients' rights or benefits. The Waksman Foundation of Japan Inc. funded the writing support and approved the publication for submission. The corresponding author confirms that he had full access to all the data in the study and takes final responsibility for the decision to submit for publication.
Funding Information:
K. Nakagome reports grants from The Waksman Foundation of Japan Inc. during the conduct of this study and from Meiji Seika Pharma, Otsuka Pharmaceutical, Dainippon Sumitomo, Mochida Pharmaceutical, Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma, Nippon Boehringer Ingelheim, Astellas Pharma, Asahi Kasei Pharma, and Shionogi and personal fees from Meiji Seika Pharma, MSD K.K., Otsuka, Kyowa Hakko Kirin, Dainippon Sumitomo, Takeda Pharmaceutical, Eli Lilly Japan K.K., Pfizer Japan, Nippon Boehringer Ingelheim, Toyama Chemical, Mochida, Janssen Pharmaceutical, Yoshitomiyakuhin Corporation, Taisho Toyama Pharma, and Kowa, outside the submitted work.
Funding Information:
T. Ohmori reports personal fees from Astellas, Daiichi Sankyo, Sumitomo Dainippon, Eisai, Eli Lilly, GlaxoSmithKline, Meiji Seika Pharma, Mochida, MSD, Novartis, Otsuka, Pfizer, Takeda, Mitsubishi Tanabe, and Yoshitomi and grants from Astellas, Dainippon Sumitomo, Eisai, Meiji Seika Pharma, Otsuka, and Pfizer.
Funding Information:
T. Kishimoto reports personal fees from Sumitomo Dainippon Pharma, Otsuka, Janssen Pharmaceutical, Meiji Seika Pharma, Eisai, MSD, Yoshitomiyakuhin, Mochida, and Takeda and grants from Eisai, Meiji Seika Pharma, Sumitomo Dainippon Pharma, Yoshitomiyakuhin, Shionogi, Mochida, MSD, Pfizer, Eli Lilly, Mitsubishi Tanabe Pharma, Otsuka, Nippon Boehringer Ingelheim, and Janssen Pharmaceutical, outside the submitted work.
Funding Information:
J. Ishigooka reports a grant from The Waksman Foundation of Japan Inc. for the work under consideration for publication and personal fees from Dainippon Sumitomo, Eisai, Eli Lilly, MSD, Novartis, Otsuka, Pfizer, Shionogi, and Takeda, outside the submitted work.
Publisher Copyright:
© 2021 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.
PY - 2022/1
Y1 - 2022/1
N2 - Aim: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety. Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. Conclusion: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
AB - Aim: Globally, evidence from short-term studies is insufficient for the guidelines to uniformly recommend a particular antipsychotic(s) for the maintenance treatment of schizophrenia. Therefore, long-term comprehensive evaluation of antipsychotics is required from a social rehabilitation perspective, especially for drugs that have not yet been studied. The Japan Useful Medication Program for Schizophrenia (JUMPs) is a large-scale, long-term naturalistic study to present pivotal 52-week data on the continuity of second-generation antipsychotics (SGA: aripiprazole, blonanserin, and paliperidone). Methods: JUMPs was an open-label, three-arm, randomized, parallel-group, 52-week study. Enrolled patients had schizophrenia, were ≥20 years old, and required antipsychotic treatment or switched from previous therapy. The primary endpoint was treatment discontinuation rate over 52 weeks. Secondary outcomes included remission rate, social functioning, and quality-of-life scores [Personal and Social Performance Scale (PSP) and EuroQol-5 dimensions], and safety. Results: In total, 251 patients received aripiprazole (n = 82), blonanserin (n = 85), or paliperidone (n = 84). The discontinuation rate (P = 0.9771) and remission rates (P > 0.05) over 52 weeks did not differ significantly between the three treatment groups. The discontinuation rates were 68.3%, 68.2%, and 65.5% in the aripiprazole, blonanserin, and paliperidone groups, respectively. Significant improvements (all P < 0.05) from baseline in PSP scores were observed at start of monotherapy, week 26, and week 52 in the overall cohort and blonanserin group and at week 26 in the aripiprazole group. The adverse event profile favored blonanserin. Conclusion: All three SGAs evaluated in this study showed similar treatment discontinuation rates in patients with chronic schizophrenia in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85119074991&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119074991&partnerID=8YFLogxK
U2 - 10.1111/pcn.13304
DO - 10.1111/pcn.13304
M3 - Article
C2 - 34626144
AN - SCOPUS:85119074991
VL - 76
SP - 22
EP - 31
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
SN - 1323-1316
IS - 1
ER -